Science & Technology


Bacterial surface attachment can be divided into three phases: (1) primary reversible adhesion, (2) secondary and irreversible adhesion, and (3) biofilm formation. Each of these phases is controlled by the expression of  proteins that mediate adhesion, replication and other functions that lead to biofilm formation and implant infection.

When a foreign body is implanted in a patient, the surface of the device rapidly becomes coated (called “conditioning”) with a mixture of water, proteins, and lipids derived from patient cells and extracellular materials. Once a surface has been conditioned, it becomes highly susceptible to bacterial colonization.

In patients suffering from orthopedic implant infections, 80% of those biofilm infections are due to Staphylococcus spp. bacteria.  We have identified staphylococcal proteins expressed early in the process of biofilm development as potential drug targets for suppressing implant infection.  In animal models of implant infection, administering antibodies against one of these proteins can inhibit biofilm formation, lower the incidence of implant infection and suppress the bone damage that often accompanies implant sepsis.

TPH 101  is a humanized, neutralizing monoclonal antibody designed to inhibit one of these key enzyme targets and to assist the patient’s own immune system in providing protection against infection during post-surgical recovery.